Orlistat-Induced Gut Microbiota Modification in Obese Mice

Area of Science:

• Microbiology
• Metabolic Disease Research
• Pharmacology

Background:

• Alterations in gut microbiota are linked to metabolic diseases.
• Orlistat, a lipase inhibitor, aids weight loss and metabolism.
• The impact of orlistat on gut microbiota composition is not well understood.

Purpose of the Study:

• To investigate the effects of orlistat on gut microbiota in mice fed a high-fat diet.
• To explore the relationship between orlistat, gut microbial changes, and metabolic parameters.

Main Methods:

• C57BL/6J mice were fed either a normal chow diet or a high-fat diet (HFD) for 6 months.
• Orlistat was administered to the HFD group during the final 3 months.
• Body weight, metabolic parameters, and gut microbial composition (via 16S rRNA sequencing) were analyzed.

Main Results:

• Orlistat treatment improved body weight, plasma cholesterol, and glucose tolerance in HFD mice.
• Orlistat altered gut microbiota, reducing total abundance and upregulating specific bacteria.
• Upregulated bacteria showed correlations with various metabolic pathways.

Conclusions:

• Orlistat may improve body weight and glucose tolerance by modulating gut microbiota composition.
• The study highlights a potential mechanism for orlistat's metabolic benefits involving gut microbial shifts.